# Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration

> **NCT03308994** · — · COMPLETED · sponsor: **University Hospital, Caen** · enrollment: 650 (actual)

## Conditions studied

- C10.114.375.500

## Interventions

- **OTHER:** Delay between MS onset and introduction of first line DMT
- **OTHER:** EDI

## Key facts

- **NCT ID:** NCT03308994
- **Lead sponsor:** University Hospital, Caen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 650 (ACTUAL)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03308994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03308994, "Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03308994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*